A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...

Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and ...

Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...

After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...

Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now soon they may be unavailable to most.

But as the drugstore chain (WBA) prepares to go private and its rival CVS Health Inc. (CVS) experiments with smaller stores, some analysts and researchers see a possible future with even fewer ...

Both Ozempic and Wegovy still posted strong double-digit ... Now, it's clear that Lilly's products are closing the gap, although Novo Nordisk and analysts have both suggested the weaker second ...

Step right up, ladies and gentlemen, and welcome to the hottest new spot in town: The Weight-Loss Casino! Here, you don’t ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...